In the present study, the pharmacological inhibition of HSP90 with PU-H71 potently depleted pro-survival kinases in patient-derived glioma cells; however, in vivo experiments in our laboratory showed that the drug has limited BBB permeability in in vivo glioma models. Here, HSP90AA1 is linked to central nervous system cancer.